STOCK TITAN
  1. Home
  2. News
  3. TARO

Taro Announces Resignation of Chief Financial Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021. Ms. Huang is leaving the Company in order to pursue other opportunities.

Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company, I want to thank Daphne for her valuable contributions including her efforts over the past year during the COVID-19 pandemic. We wish her the best in her future endeavors.”

The Company has initiated a search for a successor as Chief Financial Officer.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

Stock TARO logo
Taro Pharmaceutical Industries Ltd.

NYSE:TARO

TARO Rankings

#2111 Ranked by Market Cap
#1295 Ranked by Stock Gains
N/A Ranked by Dividends

TARO Latest News

May 15, 2024
Taro to Release Full Year Results on May 20, 2024
Apr 15, 2024
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Jan 30, 2024
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
Jan 25, 2024
Taro Provides Results for December 31, 2023
Jan 19, 2024
Taro to Release Third Quarter Results on January 25, 2024

TARO Stock Data

1.59B
8.09M
78.48%
13.45%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Haifa

About TARO

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.